Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients

BACKGROUND/OBJECTIVE: We report the first analysis of an extended half‐life recombinant factor IX, nonacog beta pegol (N9‐GP), in previously untreated patients (PUPs) and minimally treated patients with hemophilia B. METHODS: Paradigm 6 (Safety and Efficacy of Nonacog Beta Pegol [N9‐GP] in Previousl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Anthony K., Alamelu, Jayanthi, Barnes, Chris, Chuansumrit, Ampaiwan, Garly, May‐Lill, Meldgaard, Rikke Medom, Young, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles ‐ Hemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590314/
https://www.ncbi.nlm.nih.gov/pubmed/33134776
http://dx.doi.org/10.1002/rth2.12412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590314/
https://www.ncbi.nlm.nih.gov/pubmed/33134776
http://dx.doi.org/10.1002/rth2.12412

Ejemplares similares